BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29603380)

  • 1. Identification of chromatin-accessible domains in non-alcoholic steatohepatitis-derived hepatocellular carcinoma.
    Dechassa ML; Tryndyak V; de Conti A; Xiao W; Beland FA; Pogribny IP
    Mol Carcinog; 2018 Aug; 57(8):978-987. PubMed ID: 29603380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
    Jühling F; Hamdane N; Crouchet E; Li S; El Saghire H; Mukherji A; Fujiwara N; Oudot MA; Thumann C; Saviano A; Roca Suarez AA; Goto K; Masia R; Sojoodi M; Arora G; Aikata H; Ono A; Tabrizian P; Schwartz M; Polyak SJ; Davidson I; Schmidl C; Bock C; Schuster C; Chayama K; Pessaux P; Tanabe KK; Hoshida Y; Zeisel MB; Duong FH; Fuchs BC; Baumert TF
    Gut; 2021 Jan; 70(1):157-169. PubMed ID: 32217639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
    Jia Y; French B; Tillman B; French S
    Exp Mol Pathol; 2018 Aug; 105(1):144-149. PubMed ID: 30009772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
    Kutlu O; Kaleli HN; Ozer E
    Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.
    Takaki Y; Saito Y; Takasugi A; Toshimitsu K; Yamada S; Muramatsu T; Kimura M; Sugiyama K; Suzuki H; Arai E; Ojima H; Kanai Y; Saito H
    Cancer Sci; 2014 Oct; 105(10):1254-60. PubMed ID: 25117675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential open chromatin profile and transcriptomic signature define depot-specific human subcutaneous preadipocytes: primary outcomes.
    Divoux A; Sandor K; Bojcsuk D; Talukder A; Li X; Balint BL; Osborne TF; Smith SR
    Clin Epigenetics; 2018 Nov; 10(1):148. PubMed ID: 30477572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the Cell Death Pathway in Nonalcoholic Steatohepatitis (NASH)-Related Hepatocarcinogenesis Is Associated with Histone H4 lysine 16 Deacetylation.
    de Conti A; Dreval K; Tryndyak V; Orisakwe OE; Ross SA; Beland FA; Pogribny IP
    Mol Cancer Res; 2017 Sep; 15(9):1163-1172. PubMed ID: 28512251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis.
    Borowa-Mazgaj B; de Conti A; Tryndyak V; Steward CR; Jimenez L; Melnyk S; Seneshaw M; Mirshahi F; Rusyn I; Beland FA; Sanyal AJ; Pogribny IP
    Toxicol Sci; 2019 Aug; 170(2):273-282. PubMed ID: 31086990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide DNA methylation analysis during non-alcoholic steatohepatitis-related multistage hepatocarcinogenesis: comparison with hepatitis virus-related carcinogenesis.
    Kuramoto J; Arai E; Tian Y; Funahashi N; Hiramoto M; Nammo T; Nozaki Y; Takahashi Y; Ito N; Shibuya A; Ojima H; Sukeda A; Seki Y; Kasama K; Yasuda K; Kanai Y
    Carcinogenesis; 2017 Mar; 38(3):261-270. PubMed ID: 28426876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DNA methylation profile of liver tumors in C3H mice and identification of differentially methylated regions involved in the regulation of tumorigenic genes.
    Matsushita J; Okamura K; Nakabayashi K; Suzuki T; Horibe Y; Kawai T; Sakurai T; Yamashita S; Higami Y; Ichihara G; Hata K; Nohara K
    BMC Cancer; 2018 Mar; 18(1):317. PubMed ID: 29566670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
    Pinyol R; Torrecilla S; Wang H; Montironi C; Piqué-Gili M; Torres-Martin M; Wei-Qiang L; Willoughby CE; Ramadori P; Andreu-Oller C; Taik P; Lee YA; Moeini A; Peix J; Faure-Dupuy S; Riedl T; Schuehle S; Oliveira CP; Alves VA; Boffetta P; Lachenmayer A; Roessler S; Minguez B; Schirmacher P; Dufour JF; Thung SN; Reeves HL; Carrilho FJ; Chang C; Uzilov AV; Heikenwalder M; Sanyal A; Friedman SL; Sia D; Llovet JM
    J Hepatol; 2021 Oct; 75(4):865-878. PubMed ID: 33992698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
    Febbraio MA; Reibe S; Shalapour S; Ooi GJ; Watt MJ; Karin M
    Cell Metab; 2019 Jan; 29(1):18-26. PubMed ID: 30449681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase HDAC8 Promotes Insulin Resistance and β-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.
    Tian Y; Wong VW; Wong GL; Yang W; Sun H; Shen J; Tong JH; Go MY; Cheung YS; Lai PB; Zhou M; Xu G; Huang TH; Yu J; To KF; Cheng AS; Chan HL
    Cancer Res; 2015 Nov; 75(22):4803-16. PubMed ID: 26383163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant DNA methylation results in altered gene expression in non-alcoholic steatohepatitis-related hepatocellular carcinomas.
    Tian Y; Arai E; Makiuchi S; Tsuda N; Kuramoto J; Ohara K; Takahashi Y; Ito N; Ojima H; Hiraoka N; Gotoh M; Yoshida T; Kanai Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2461-2477. PubMed ID: 32685988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.
    Yang H; Deng Q; Ni T; Liu Y; Lu L; Dai H; Wang H; Yang W
    Int J Biol Sci; 2021; 17(15):4207-4222. PubMed ID: 34803493
    [No Abstract]   [Full Text] [Related]  

  • 18. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
    Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
    World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease.
    Tian Y; Wong VW; Chan HL; Cheng AS
    Semin Cancer Biol; 2013 Dec; 23(6 Pt B):471-82. PubMed ID: 24018165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.